BioNexus Gene Lab (BGLC) CEO files Form 3 showing 0.0000 shares
Rhea-AI Filing Summary
BioNexus Gene Lab Corp disclosed that CEO and director Tan Lee Su-Leng filed a Form 3 reporting her holdings of company equity securities. The report lists 0.0000 shares held directly following a holdings entry dated 2023-08-15, with no buy or sell transactions shown.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Tan Lee Su-Leng
Role
CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | 0 | -- | -- | -- |
Holdings After Transaction:
0 — 0 shares (Direct)
Key Figures
Shares held after reported entry: 0.0000 shares
Holding entries reported: 1
Insider purchase transactions: 0
3 metrics
Shares held after reported entry
0.0000 shares
Direct holdings reported following the 2023-08-15 holdings entry
Holding entries reported
1
Number of holdings rows reported in this Form 3
Insider purchase transactions
0
Buy transactions and shares reported in the transaction summary
Key Terms
Rule 10b5-1, beneficial ownership, direct_or_indirect
3 terms
Rule 10b5-1 regulatory
"Footnotes may reference Rule 10b5-1 trading plans."
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
beneficial ownership regulatory
"Footnotes may reference disclaimers of beneficial ownership."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
direct_or_indirect technical
"direct_or_indirect uses D/I for Direct/Indirect ownership type."
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does the BioNexus Gene Lab Corp (BGLC) Form 3 report?
The Form 3 reports that CEO and director Tan Lee Su-Leng has 0.0000 directly held shares of BioNexus Gene Lab Corp as of a holdings entry dated 2023-08-15, with no purchases or sales listed.
Does the BioNexus Gene Lab (BGLC) Form 3 show any insider buying or selling?
No. The transaction summary shows 0 buy transactions and 0 sell transactions. The Form 3 only records a holdings entry with 0.0000 shares and no reported purchases or sales.
What is the date associated with Tan Lee Su-Leng’s BGLC holdings entry?
The holdings entry for BioNexus Gene Lab Corp (BGLC) is dated 2023-08-15. As of that date, the Form 3 shows 0.0000 directly held shares for CEO and director Tan Lee Su-Leng.
Is the BGLC CEO’s reported ownership direct or indirect?
The Form 3 reports the CEO’s holdings as direct ownership, with an ownership code of D. The total shares following the reported holdings entry are listed as 0.0000 shares.